MacroGenics Inc (OQ:MGNX)

May 03, 2024 07:30 am ET
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Apr 03, 2024 04:30 pm ET
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the Phase 2...
Mar 07, 2024 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate...
Mar 01, 2024 05:48 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management...
Feb 27, 2024 05:45 pm ET
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Feb 02, 2024 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management...
Jan 08, 2024 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management...
Nov 06, 2023 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and...
Nov 02, 2023 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Oct 31, 2023 04:30 pm ET
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Sep 05, 2023 07:00 am ET
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc....
Aug 31, 2023 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Aug 09, 2023 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Jul 31, 2023 05:35 pm ET
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
May 09, 2023 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
May 04, 2023 04:30 pm ET
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Apr 24, 2023 06:15 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Mar 22, 2023 01:22 pm ET
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’s (FDA)...
Mar 15, 2023 04:01 pm ET
MacroGenics Provides Corporate Update and 2022 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Mar 14, 2023 08:00 am ET
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
MacroGenics adds up to four ADC programsMacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix's linker-payload technologiesExpanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net salesAMSTERDAM, March 14, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has announced the expansion of its license agreement with Macro
Mar 08, 2023 05:36 pm ET
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has entered into an agreement to sell...
Mar 07, 2023 06:00 pm ET
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Mar 02, 2023 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Feb 13, 2023 05:20 pm ET
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity...
Feb 06, 2023 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Jan 04, 2023 05:50 pm ET
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual...
Jan 04, 2023 04:30 pm ET
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra...
Nov 17, 2022 06:10 pm ET
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the...
Nov 03, 2022 04:01 pm ET
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Nov 02, 2022 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Oct 26, 2022 04:30 pm ET
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Oct 17, 2022 09:57 am ET
Thinking about buying stock in MacroGenics, Anavex Life Sciences, Uber Technologies, IVERIC bio, or Roblox?
NEW YORK,, Oct. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, AVXL, UBER, ISEE, and RBLX.
Oct 17, 2022 07:30 am ET
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Sep 02, 2022 07:00 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Aug 08, 2022 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Jul 25, 2022 04:01 pm ET
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Jul 08, 2022 04:30 pm ET
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022, the Company closed the...
Jun 08, 2022 04:01 pm ET
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
May 23, 2022 04:01 pm ET
MacroGenics Announces Appointment of William Heiden to Board of Directors
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors,...
May 17, 2022 04:01 pm ET
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
May 03, 2022 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Apr 25, 2022 04:11 pm ET
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Mar 03, 2022 04:01 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the...
Feb 28, 2022 07:00 am ET
MacroGenics Announces Executive Promotion
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer,...
Feb 24, 2022 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported...
Feb 14, 2022 04:01 pm ET
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Feb 03, 2022 04:01 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in...
Nov 03, 2021 04:01 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in...
Nov 02, 2021 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and...
Oct 26, 2021 04:30 pm ET
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Sep 16, 2021 02:45 am ET
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced results from Cohort A Part 1 of the Phase 2/3...
Sep 16, 2021 02:45 am ET
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor activity data...
Sep 12, 2021 07:00 pm ET
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple...
Sep 07, 2021 04:30 pm ET
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the...
Sep 02, 2021 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in...
Aug 05, 2021 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate...
Jul 29, 2021 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and...
Jul 22, 2021 04:05 pm ET
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Jun 17, 2021 02:49 pm ET
MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors...
Jun 16, 2021 05:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 16, 2021 07:30 am ET
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative...
Jun 16, 2021 07:30 am ET
Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based...
Jun 14, 2021 08:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jun 08, 2021 05:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
May 19, 2021 05:05 pm ET
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary safety and anti-tumor...
May 19, 2021 07:00 am ET
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate...
Apr 29, 2021 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and...
Apr 19, 2021 04:30 pm ET
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Apr 10, 2021 08:30 am ET
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American Association for...
Feb 26, 2021 07:30 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate...
Feb 25, 2021 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and...
Feb 18, 2021 04:30 pm ET
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...
Feb 11, 2021 04:30 pm ET
MacroGenics Names Federica O’Brien to its Board of Directors
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien,...
Feb 11, 2021 07:30 am ET
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved...
Feb 08, 2021 07:30 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate...
Jan 25, 2021 07:30 am ET
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of results from the SOPHIA trial...
Jan 11, 2021 08:45 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate...
Dec 22, 2020 11:35 am ET
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript on MGD019, an...
Dec 18, 2020 07:30 am ET
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license...
Dec 17, 2020 08:31 am ET
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV.
Dec 16, 2020 08:15 pm ET
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
Zai Lab Limited’s (NASDAQ: ZLAB; HKEX: 9688) partner MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, today...
Dec 16, 2020 04:30 pm ET
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
Dec 07, 2020 07:30 am ET
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a dose...
Dec 06, 2020 01:00 pm ET
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a...
Nov 30, 2020 04:30 pm ET
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with...
Nov 30, 2020 07:30 am ET
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in milestones have...
Nov 09, 2020 05:00 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management...
Nov 04, 2020 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and...
Nov 04, 2020 02:30 pm ET
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and preclinical...
Oct 28, 2020 04:30 pm ET
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
Oct 15, 2020 04:30 pm ET
MacroGenics Announces Flotetuzumab Publication in Blood Advances
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a...
Sep 23, 2020 07:15 am ET
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in...
Sep 22, 2020 04:30 pm ET
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript...
Sep 21, 2020 07:30 am ET
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $15 million milestone payment...
Sep 20, 2020 09:10 am ET
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced clinical data from the dose...
Sep 03, 2020 07:30 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Aug 05, 2020 04:30 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Jul 30, 2020 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and...
Jul 23, 2020 07:30 am ET
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
Jul 09, 2020 06:43 pm ET
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology has published...
Jun 22, 2020 09:00 am ET
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American...
Jun 16, 2020 07:30 am ET
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Stephen Eck,...
Jun 05, 2020 09:31 am ET
Thinking about trading options or stock in Novavax, Southwest Airlines, Las Vegas Sands, Carnival Corp, or MacroGenics?
NEW YORK, June 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVAX, LUV, LVS, CCL, and MGNX.
Jun 05, 2020 07:30 am ET
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
Jun 03, 2020 04:05 pm ET
MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced research published in the journal...
May 28, 2020 07:30 am ET
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that during the recent mid-cycle...
May 27, 2020 07:30 am ET
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study...
May 21, 2020 04:05 pm ET
MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call and...
May 13, 2020 05:10 pm ET
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two of...
May 12, 2020 09:31 am ET
Thinking about buying stock in MacroGenics, BioCryst Pharmaceuticals, American Airlines, Revolve Group, or Microsoft Corp?
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, BCRX, AAL, RVLV, and MSFT.
May 06, 2020 11:00 am ET
Thinking about buying stock in IZEA Worldwide, Microvision, MacroGenics, Pinterest, or Activision Blizzard?
NEW YORK, May 6, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IZEA, MVIS, MGNX, PINS, and ATVI.
May 05, 2020 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and...
Apr 29, 2020 04:01 pm ET
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations at the...
Apr 28, 2020 04:01 pm ET
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting of...
Apr 28, 2020 07:30 am ET
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
Apr 27, 2020 12:05 am ET
MacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab, an...
Mar 04, 2020 05:00 pm ET
MacroGenics Announces Departure of Chief Medical Officer
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that Jon Wigginton, M.D., Senior Vice...
Feb 27, 2020 07:30 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Feb 25, 2020 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate...
Feb 13, 2020 07:30 am ET
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
Feb 10, 2020 07:30 am ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Jan 13, 2020 07:30 am ET
MacroGenics to Present at the J.P. Morgan Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will present at the...
Jan 09, 2020 04:30 pm ET
MacroGenics Outlines Corporate Priorities for 2020
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and program...
Dec 19, 2019 12:00 pm ET
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a...
Dec 11, 2019 10:00 am ET
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3...
Dec 09, 2019 03:05 pm ET
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 1/2...
Dec 02, 2019 07:30 am ET
MacroGenics to Participate in the Evercore ISI HealthCONx Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Nov 12, 2019 10:59 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MGNX, OSTK, RUHN and REZI
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 12, 2019 10:29 am ET
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or “the Company”) (NASDAQ:
Nov 12, 2019 09:36 am ET
CLASS ACTION UPDATE for SNDL, DBX, MGNX and WTRH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 12, 2019 09:00 am ET
DEADLINE ALERT - MacroGenics, Inc. (MGNX) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: November 12, 2019
NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics"  or "the Company") (NASDAQ: MGNX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired MacroGenics securities between February 6, 2019 and June 3, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/mgnx.   
Nov 11, 2019 09:41 am ET
SHAREHOLDER ALERT: PUMP MGNX VRAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 10, 2019 12:00 pm ET
2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds MacroGenics (MGNX) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact th
Hagens Berman urges MacroGenics (NASDAQ: MGNX) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. Only two days remain until the November 12, 2019 lead...
Nov 09, 2019 11:52 am ET
ROSEN, A LEADING GLOBAL LAW FIRM, Reminds MacroGenics, Inc. Investors of Important November 12th Deadline in Securities Class Action – MGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Nov 08, 2019 04:59 pm ET
MGNX NOTICE: Zhang Investor Law Reminds Investors of November 12 Deadline in Securities Class Action Lawsuit Against MacroGenics, Inc.- MGNX 
Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of MacroGenics, Inc. (NASDAQ: MGNX) between February 6, 2019 and June 3, 2019, inclusive (the “Class Period”). If you wish to serve as lead...
Nov 08, 2019 03:00 pm ET
DEADLINE ALERT - MacroGenics, Inc. (MGNX) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: November 12, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics”  or “the Company”) (NASDAQ: MGNX) and certain of its officers, on behalf of...
Nov 08, 2019 11:20 am ET
SHAREHOLDER ALERT: SEE UNIT MGNX UBER: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 07, 2019 04:45 pm ET
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will...
Nov 07, 2019 04:39 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in MGNX, ERI, and SNDL of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of MGNX, ERI, and SNDL. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Nov 07, 2019 09:25 am ET
CLASS ACTION UPDATE for PUMP, MGNX, IRBT and TWTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 06, 2019 05:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased MacroGenics, Inc. (NASDAQ: MGNX) securities between February 6, 2019 and June 3, 2019  ("the "Class Period").  Investors have until November 12, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Nov 06, 2019 04:01 pm ET
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and...
Nov 06, 2019 09:30 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PUMP, MGNX, TME and UBER
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 06, 2019 09:12 am ET
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and preclinical...
Nov 05, 2019 08:00 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MacroGenics (MGNX) Investors With Significant Losses to Contact Its Attorneys Now, 7-Day Application Deadline is Approaching
Hagens Berman urges MacroGenics (NASDAQ: MGNX) investors who have suffered losses in excess of $50,000 to submit their loss now to learn if they qualify to recover their investment losses.  The November 12, 2019 lead plaintiff deadline in a...
Nov 05, 2019 10:00 am ET
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against MacroGenics, Inc. (MGNX) and November 12 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is reminding investors that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX), and certain other defendants, related to alleged violations of federal sec
Nov 04, 2019 04:00 pm ET
IMPORTANT REMINDER FOR MACROGENICS, INC. INVESTORS: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District
Wolf Haldenstein Adler Freeman & Herz LLP   announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased MacroGenics, Inc....
Nov 04, 2019 03:57 pm ET
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 4, 2019) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 04, 2019 12:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Nov 04, 2019 09:20 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PUMP, MGNX, VRAY and DOMO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 01, 2019 03:00 pm ET
Shareholder Alert - Greenlane Holdings, Inc. (GNLN), MacroGenics, Inc. (MGNX) & ViewRay, Inc. (VRAY)  - Bronstein, Gewirtz & Grossman, LLC Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Nov 01, 2019 01:11 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in MGNX, ERI, and SNDL of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of MGNX, ERI, and SNDL. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Nov 01, 2019 12:14 pm ET
CLASS ACTION UPDATE for MGNX, MO, MTCH and TWTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 01, 2019 11:29 am ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against MacroGenics, Inc.- MGNX
Pawar Law Group announces that a class action lawsuit on behalf of shareholders who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...
Oct 31, 2019 09:41 am ET
CLASS ACTION UPDATE for ADTN, MDP, MGNX and VRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 31, 2019 07:00 am ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds MacroGenics (MGNX) Investors of Securities Class Action: Encourages Investors Who Have Suffered Losses to Contact Firm
Hagens Berman reminds investors in MacroGenics (NASDAQ: MGNX) of the securities fraud class action filed against the company and urges MGNX investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Feb. 6, 2019 –...
Oct 30, 2019 04:05 pm ET
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its...
Oct 30, 2019 04:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of MacroGenics, Inc. (NASDAQ: MGNX), ViewRay, Inc. (NASDAQ: VRAY), Cadence Bancorp...
Oct 28, 2019 04:45 pm ET
ROSEN, A HIGHLY RANKED LAW FIRM, Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Class Action – MGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Oct 25, 2019 03:49 pm ET
Zhang Investor Law Reminds Investors of November 12 Deadline in Securities Class Action Lawsuit Against MacroGenics, Inc.- MGNX
Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of MacroGenics, Inc. (NASDAQ: MGNX) between February 6, 2019 and June 3, 2019, inclusive (the “Class Period”). If you wish to serve as lead...
Oct 25, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 25, 2019 09:55 am ET
SHAREHOLDER ALERT: MGNX CADE MTCH TME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 25, 2019 08:30 am ET
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that its partner MacroGenics, Inc. (NASDAQ: MGNX) has dosed the first patient in the Phase 2/3 MAHOGANY clinical trial of...
Oct 25, 2019 07:30 am ET
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been...
Oct 24, 2019 09:40 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MGNX, CADE, OSTK and MYGN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Oct 23, 2019 07:09 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canada Goose, Meredith Corporation, MacroGenics, and ViewRay and Encourages Investors to Contact the Fi
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Goose Holdings, Inc. (NYSE: GOOS), Meredith Corporation (NYSE: MDP),...
Oct 23, 2019 05:19 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Oct 23, 2019 04:04 pm ET
IMPORTANT REMINDER FOR MACROGENICS, INC. INVESTORS: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Dist
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased MacroGenics, Inc. (NASDAQ:...
Oct 23, 2019 09:22 am ET
CLASS ACTION UPDATE for MGNX, VRAY, MTCH and CVET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 22, 2019 08:00 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, REMIND MACROGENICS (MGNX) INVESTORS OF SECURITIES CLASS ACTION: Firm Encourages Investors Who Have Suffered Losses to Contact the Firm Now
Hagens Berman Sobol Shapiro LLP reminds investors in MacroGenics (MGNX) of the securities fraud class action filed against the company and urges MGNX investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Feb....
Oct 22, 2019 04:30 pm ET
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from the second...
Oct 22, 2019 02:33 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in MGNX, ERI, and SNDL of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of MGNX, ERI, and SNDL. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 19, 2019 01:00 pm ET
ROSEN, A LEADING LAW FIRM, Reminds MacroGenics, Inc. Investors of Important November 12th Deadline in Securities Class Action – MGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Oct 18, 2019 04:44 pm ET
MACROGENICS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 18, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 18, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 17, 2019 10:57 am ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in MGNX, ERI, and SNDL of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of MGNX, ERI, and SNDL. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 16, 2019 04:00 pm ET
IMPORTANT REMINDER FOR MACROGENICS, INC. INVESTORS: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Dist
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all investors that purchased MacroGenics, Inc. (NASDAQ:...
Oct 16, 2019 09:22 am ET
CLASS ACTION UPDATE for MGNX, OLLI, MTCH and OSTK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 16, 2019 07:35 am ET
MGNX INVESTOR REMINDER: Hagens Berman Reminds MacroGenics (MGNX) Investors of Securities Class Action, Encourages Investors Who Lost $50,000+ to Contact the Firm
Hagens Berman Sobol Shapiro LLP reminds investors in MacroGenics (MGNX) of the securities fraud class action filed against the company and urges MGNX investors who have suffered losses in excess of $50,000 to contact the firm. Class Period: Feb. 6,...
Oct 15, 2019 11:40 pm ET
MACROGENICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 15, 2019 08:54 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Macrogenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Macrogenics, Inc. (NASDAQ: MGNX), ViewRay, Inc. (NASDAQ: VRAY), Cadence Bancorp (NYSE: CADE), and ProPetro Holding Corp....
Oct 15, 2019 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Oct 11, 2019 03:00 pm ET
Class Action - MacroGenics, Inc. (MGNX), ViewRay, Inc. (VRAY) & Cadence Bancorporation (CADE) - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 10, 2019 12:22 pm ET
MACROGENICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 10, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 09, 2019 04:05 pm ET
ROSEN, A TOP RANKED FIRM, Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Class Action – MGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff...
Oct 09, 2019 11:20 am ET
CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in VRAY, MDP, and MGNX of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of VRAY, MDP, and MGNX. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 09, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to C
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Canada Goose Holdings, Inc. (NYSE: GOOS), Meredith Corporation (NYSE: MDP), and...
Oct 08, 2019 01:51 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Oct 07, 2019 08:09 pm ET
MGNX INVESTOR REMINDER: Hagens Berman Reminds MacroGenics (MGNX) Investors of Securities Class Action, Encourages Investors Who Lost $50,000+ to Contact the Firm
Hagens Berman Sobol Shapiro LLP reminds MGNX investors of a securities fraud lawsuit filed against MacroGenics, Inc. (MGNX). CLASS PERIOD: Feb. 6, 2019 – June 3, 2019 LEAD PLAINTIFF DEADLINE: Nov. 12, 2019 Email:   [email protected] Visit:...
Oct 05, 2019 02:30 pm ET
ROSEN, A LEADING LAW FIRM, Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Class Action - MGNX
NEW YORK, Oct. 5, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the "Class Period") of the important November 12, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for MacroGenics investors under the federal securities laws.
Oct 04, 2019 03:00 pm ET
SHAREHOLDER ALERT - MacroGenics, Inc. (MGNX) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: November 12, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics”  or “the Company”) (NASDAQ: MGNX) and certain of its officers, on behalf of...
Oct 04, 2019 09:29 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TWOU, SRPT, SNDL and MGNX
NEW YORK, October 4, 2019 – The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court...
Oct 02, 2019 09:07 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta Therapeutics, Canada Goose, Meredith Corporation, and MacroGenics and Encourages Investors to C
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Canada Goose Holdings, Inc. (NYSE: GOOS), Meredith Corporation (NYSE: MDP), and...
Oct 02, 2019 10:11 am ET
CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in VRAY, MDP, and MGNX of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of VRAY, MDP, and MGNX. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead...
Oct 02, 2019 09:33 am ET
CLASS ACTION UPDATE for GNLN, PS, GVA and MGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Oct 02, 2019 09:13 am ET
MACROGENICS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In MacroGenics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 2, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MacroGenics, Inc. (NASDAQ: MGNX) ("MacroGenics" or the "Company") of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Oct 01, 2019 08:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc. - MGNX
Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Sep 30, 2019 08:15 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds MacroGenics, Inc. Investors of Important Deadline in Securities Class Action - MGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MacroGenics, Inc. (NASDAQ: MGNX) from February 6, 2019 through June 3, 2019, inclusive (the “Class Period”) of the important November 12, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for MacroGenics investors under the federal securities laws.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.